+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance

A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance

Advances in Cancer Research 85: 145-174

Tumor resistance to conventional therapies is a major problem in cancer treatment. While tumors initially respond to radiation or chemotherapies, subsequent treatments with these conventional modalities are ineffective against relapsed tumors. The problem of tumor resistance to chemotherapy and radiation has led to the development of immunotherapy and gene-based therapies. These alternative therapeutic approaches are intensely explored because they are supposed to be more tumor specific and better tolerated than the conventional therapies. Recent advances in apoptosis have revealed that resistance to apoptosis is one of the major mechanisms of tumor resistance to conventional therapies. Resistance to apoptosis is a naturally acquired characteristic during oncogenesis and is selected for after successive rounds of conventional therapies. Resistance to apoptosis involves dysregulation and/or mutation of apoptotic signaling molecules that render tumor cells unresponsive to apoptotic stimuli. Since both immunotherapy and chemotherapy kill tumors by apoptosis and the killings are signaled through a central core apoptotic program, dysregulation of this central program and development of resistance to apoptosis in chemoresistant cells could render them cross-resistant to immunotherapy. Therefore, in order to establish an effective antitumor response and to complement immunotherapy and gene-based therapies, cross-resistance due to resistance to apoptosis must be overcome. In this review, based on prior findings and recent evidence, we put forth a model, verified experimentally, in which chemoresistant tumor cells can be sensitized to immune-mediated killing by subtoxic concentrations of chemotherapeutic drugs/factors. The model involves two complementary signals. The first signal is a sensitizing signal that regulates pro/antiapoptotic targets, thus facilitating the apoptotic signal. The second apoptotic signal initiates a partial activation of the apoptotic signaling pathway, and activation is completed by complementation with signal one. Thus, effective killing of immunoresistant cells is achieved by both signals. The two-signal approach provides a new strategy to overcome cancer cross-resistance to immunotherapy and opens new avenues for the development of more effective and selective immunosensitizing agents.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 045079341

Download citation: RISBibTeXText

PMID: 12374285

Related references

Strategies to overcome obstacles to successful immunotherapy of melanoma. International Journal of Immunopathology and Pharmacology 21(3): 493-500, 2008

Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. Il Giornale di Chirurgia 37(5): 225-235, 2017

Induction of apoptosis by rho in NIH 3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis. Oncogene 11(12): 2657-2665, 1995

Identification and deconvolution of cross-resistance signals from antimalarial compounds using multidrug-resistant Plasmodium falciparum strains. Antimicrobial Agents and ChemoTherapy 59(2): 1110-1118, 2015

CD2-mediated IL-12-dependent signals render human gammadelta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: Implications for the development of adoptive immunotherapy strategies. Blood 96(12): 3827-3837, December 1, 2000

Cross resistance studies in degranol resistant NK-ly ascites tumors. Zeitschrift für Krebsforschung 68(2): 184-189, 1966

Studies of cross-resistance in Degranol-resistant NK/ly ascites tumors. Z Krebsforsch 68(2): 184-189, 1966

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy. International Journal of Molecular Sciences 19(12), 2018

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Trends in Immunology 2019, 2019

The challenge of developing robust drugs to overcome resistance. Drug Discovery Today 16(17-18): 755-761, 2012

Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. Journal of Leukocyte Biology 102(3): 727-740, 2017

Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells. Frontiers in Oncology 4: 270, 2014

Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. Bmc Cancer 18(1): 1082, 2019

Complete lack of cross-resistance of cisplatin-resistant tumors to a novel charged trinuclear platinum complex p53-independent antitumor efficacy. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 310, 1997

Exploiting the TSA connections to overcome apoptosis-resistance. Cancer Biology and Therapy 4(4): 391-392, 2005